Company Profile

SweeGen, Inc. is a development-stage company. The Company intends to leverage the experience of its new corporate and scientific management team, which has experience in managing and developing large and small private and public companies; pathway engineering; microbial platform development, and developing and manufacturing food ingredients, biological products, dietary supplements and botanical extracts. The Company focuses on seeking, developing and acquiring, completely or a substantial interest in, companies or assets. The Company's subsidiary is Phytosub, Inc. As of June 30, 2016, the Company had not generated any revenues.

Employees

Sector

Food Processing

More about the company

31/08/23	Sweegen's Rebaudioside M Sweetener Technology Receives Regulatory Approval in Taiwan	CI
05/12/22	Sweegen, Inc. Announces Growth Capital Investments and Manufacturing Partnership with Sumitomo Chemical Co	CI
04/12/22	SweeGen, Inc. announced that it has received funding from Sumitomo Chemical Company, Limited, Pasaca Capital, Inc.	CI
08/07/22	Conagen and Sweegen Teams Up to Develop Modern Natural Sweeteners	CI
05/04/22	Sweegen’s Signature Stevia Receives Approval in Colombia	CI
15/03/22	Sweegen Expands Signature Stevia Footprint in Mexico	CI
01/02/22	Sweegen Blazes New Territory in Sugar Reduction with Forward Progress in Brazzein	CI
04/10/21	Sweegen Expands Sugar Reduction Portfolio with High-Intensity Sweetener Brazzein	CI
16/09/21	Sweegen Announces Premiumization of Low-Calorie Confectionery Chocolate	CI
15/07/21	European Union Commission Publishes Approval of Sweegen’S Non-Gmo Signature Bestevia Rebaudioside M (Reb M) for Use in Food and Beverages	CI
04/05/21	The Malaysia Ministry of Health Accepts Sweegen?s Zero-Calorie Bestevia Sweeteners, Rebaudiosides D, E and M for Use as Ingredients in Food and Beverage Products	CI
14/04/21	SweeGen’s Bestevia Reb M Heads to Final Approval in European Union	CI
15/03/21	SweeGen’s Bestevia® Rebaudioside B Receives U.S. FDA GRAS No Objection Letter	CI

15/10/20	PTAB: Inadvertent Mistake In Analysis Of Experimental Data That Substantially Impacts Proceeding Cannot Be Corrected	AQ
02/04/20	Sumitomo Chemical : Invests in Conagen, U.S. Bio-Venture	AQ

Manager	Title	Age	Since
Steven Chen CEO	Chief Executive Officer	61	22/12/2014
Jeremy Klaperman DFI	Director of Finance/CFO	-	-
Michael Halvorsen PRN	Corporate Officer/Principal	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SWEEGEN, INC.	-4.55%	-.--%	-	-	15.37M
GUANGXI YUEGUI GUANGYE HOLDINGS CO., LTD.	-10.01%	+11.52%	+106.27%	+331.31%	2.85B
SÜDZUCKER AG	+2.17%	-0.53%	+2.55%	-32.94%	2.67B
COSUMAR SA	+0.96%	-0.88%	-23.53%	-3.41%	1.83B
ADECOAGRO S.A.	-0.34%	+2.01%	+25.40%	+20.48%	1.68B
ILLOVO SUGAR (MALAWI) PLC	0.00%	+0.00%	+95.39%	+212.11%	1.44B
ZAMBIA SUGAR PLC	0.00%	+0.01%	+65.67%	+283.89%	1.25B
BALRAMPUR CHINI MILLS LIMITED	-1.57%	+1.53%	-11.53%	+34.53%	1.2B
SÃO MARTINHO S.A.	-8.14%	-6.40%	-21.70%	-56.74%	1.01B
TRIVENI ENGINEERING & INDUSTRIES LIMITED	+0.88%	+5.11%	-8.47%	+35.87%	889M
Average	-2.06%	-0.31%	+25.56%	+91.68%	1.65B
Weighted average by Cap.	-2.08%	-0.28%	+32.75%	+105.30%

SweeGen, Inc. Share Price Other OTC

Stocks

SWEE

US8703341094

Food Processing

Latest news : SweeGen, Inc.

Press Releases: SweeGen, Inc.

Quotes and Performance

Managers and Directors: SweeGen, Inc.

Sugar & Artificial Sweeteners

Company Profile